Australia: Raising the bar? The new patent law reforms and their impact on patentability of genetic material

Commercial Law Update
Last Updated: 15 September 2011
Article by Catherine Logan, Wen Liu and Phillip Ng

This article was first published in the Lexis Nexis Australian Intellectual Property Law Bulletin August 2011 Vol 24 No 4.

On 22 June 2011, the Intellectual Property Laws Amendment (Raising the Bar) Bill 2011 (Cth) (the Bill) was introduced to the Senate. If passed, it will represent the most significant reform of Australia's patent laws in recent history.

While the scope of the Bill is extensive, this article will specifically focus on the substantive patent reforms set out in Schs 1 and 2 of the Bill. The article then examines these proposed patent reforms in light of the broader public debate regarding the ethics and validity of gene patents.


An exposure draft of the Bill was first released in March 2011 and received much public comment and criticism. The release of the exposure draft followed a series of reports and inquiries, including the Australian Law Reform Commission (ALRC) report on gene patenting and health released in June 2004,1 Australian Council on Intellectual Property (ACIP) reports released in November 2005 and February 2011,2 a Senate Committee inquiry3 and IP Australia consultations. The Bill incorporates some, but not all, of the changes recommended by those reports and inquiries.

What are the key changes for patent applications?

Schedule 1 of the Bill proposes a number of significant changes to the Patents Act 1990 (Cth) (the Act), including the following.

  • Increasing the patent examiner's powers: The Bill will remove the current restrictions on the type of information that patent examiners may consider when determining whether an application discloses an "inventive step" or an "innovative step". Also, examiners will be entitled to consider matters beyond "inventive step" and "novelty" during the reexamination stage.
  • Increasing the threshold for patentability: There is a more stringent test for the usefulness of a patent requiring a demonstration of "specific, substantial and credible use". Further, there is a new requirement that applications must disclose the usefulness of the patent in the specification, and the examiner must report on the usefulness of an application at the examination stage (rather than this only being raised by interested parties at the opposition stage).
  • More disclosure: The Bill increases the standard and amount of information which applicants are required to disclose to satisfy a provisional application. If the application has incomplete information, it could impact on the priority date.
  • Consistent standard of proof: The Bill replaces the existing inconsistent standards of proof with a new consistent "on the balance of probabilities" standard. This replaces the applicant friendly "benefit of the doubt" test for the granting of patents, and also changes the requirement that an examiner be "practically certain" that a granted patent would be invalid before rejecting the application.
  • Limiting amendments to patent applications: There is a new prohibition on amendments to applications which add new material to the disclosure contained in the specifications as filed. Any such amendment will be refused where it seeks to add material that a hypothetical skilled person could not directly derive by reading the information in the specification as filed.

New exemptions against patent Infringement

Schedule 2 of the Bill expands and clarifies the types of activities that may be undertaken without infringing on the patent holder's rights.

Regulatory approval exemption

"Springboarding" refers to laws that allow generic companies to conduct activities that relate to obtaining regulatory permits and approval prior to the expiry date of a patent. Without springboarding laws, the monopoly enjoyed by a patent holder extends beyond the 20 years contemplated by the Act. Also, competitors from countries where springboarding is permitted are able to enter the market faster than an Australian generic company.

In 2006, the Act was amended to allow springboarding in relation to pharmaceutical products. The Bill proposes to expand this exemption to all products requiring regulatory approval. The activities must be undertaken solely for the purpose of obtaining regulatory approval, and would not apply to activities undertaken for a concurrent commercial purpose.

Research exemption

Currently, there is no exemption under the Act for research and experimental use of a patented invention. In practice, research institutions tend to rely on an assumed implicit freedom to conduct research and experiments.4 However, recent attempts by Genetic Technologies Limited (GTG) to enforce its BRCA patents (as discussed below) highlight the uncertainty faced by researchers where patent rights are involved.

The Bill introduces a specific legislative exemption for acts done for experimental purposes and a nonexhaustive list of activities that would fall under the exemption. This list currently exempts the following activities relating to a patent:

  • determining the properties of an invention;
  • determining the scope of a claim relating to the invention;
  • improving or modifying the invention;
  • determining the validity of the patent or of a claim relating to the invention; or
  • determining whether the patent or the invention would be, or has been, infringed by the doing of an act.

What is considered as "experimental purposes" is otherwise undefined and the word "experimental" is intended to have its ordinary English meaning.5

The Explanatory Memorandum to the Bill states that the exemption is sufficiently broad to encompass activities that may have future commercial applications, as long as they are conducted primarily for the purpose of research rather than having a predominantly commercial purpose.

The activities need to "relate to" the patented invention in the sense that it forms part of the subject matter of the experiment, whether as a central topic of research or subsidiary to it. Therefore, patented tools used for research but which do not form the topic of research will not be exempt.

When will these changes take effect?

If the Bill is passed, the Sch 1 changes will commence 12 months from the date of royal assent. This translates into a date in late 2012, assuming that the Bill is passed by Parliament relatively speedily. Importantly, the Sch 1 changes will not apply to patent applications where a request for examination has been filed before the date of commencement. Applicants who want the benefit of the current patents regime should therefore file their request for examination as soon as possible.

The Sch 2 changes will commence the day after the new legislation receives royal assent.

Gene patenting in Australia

Patents over genetic material have received much attention. Although the current law specifically excludes the patenting of "human beings and the biological processes for their generation",6 gene patents are granted for isolated genetic material that satisfies the tests for patentability. The controversy lies in the fact that unrestrained monopolies on genetic material may have a profoundly adverse impact on researchers and the public.

At the centre of the global debate are patents held over the BRCA1 and BRCA2 genes, which are associated with the development of breast and ovarian cancer.7 A US District Court in 2010 held that the BRCA genes were not "markedly different" from natural DNA, and the claims for analysing and comparing the genes were"mental processes" and therefore not patentable under US patent laws.8

GTG is the exclusive licence holder of the BRCA gene patents in Australia. In 2002-2003 and 2008, GTG sparked headlines when it issued "cease and desist" letters to hospitals and laboratories across Australia to prevent them from carrying out testing in relation to the BRCA genes.9 Although GTG ultimately withdrew its threats on both occasions, its actions have provoked general public outcry, the overhauling of GTG's own board of directors10 (twice), two Senate Standing Committee inquiries,11 the introduction of a private member's Bill in the Australian Parliament,12 and a pending case in the Federal Court of Australia.13

Legislative interventions

The Patent Amendment (Human Genes and Biological Materials) Bill 2010 (No 2) (Cth) (Heffernan Bill), introduced by Senators Heffernan, Coonan, Siewert and Xenophon, was a direct response to GTG's actions. It sought to expand the current ban on patenting biological material to include:

... biological materials including their components and derivatives, whether isolated or purified or not and however made, which are identical or substantially identical to such materials as they exist in nature.14

Many observers, including the ACIP, are critical of such a blanket prohibition. Their concern is that the broad language used in the Heffernan Bill will cause uncertainty for the entire biotechnology industry, with no clear benefit for the general community. A further Senate Committee inquiry was convened to examine its potential impact. That Committee's report is scheduled to be released on 21 September 2011.

The current Bill before the Senate addresses the issue of gene patents in a manner that steers away from the subject matter prohibition in the Heffernan Bill. By raising the threshold of the tests for patentability, it prevents patents over genes that are not sufficiently inventive, novel or useful. This is arguably a better means of improving the quality of gene patents without eroding commercial incentives for the biotechnology industry.

In addition, the Bill's exemption for experimental use gives greater certainty to researchers on their right to conduct research and also to patent holders on when they can enforce their rights, but fails to deal with public health access issues. For example, in the case of the BRCA gene patents, the exemption leaves hospitals and cancer screening services in a grey area as their role is arguably more commercial than experimental. Interestingly, the Bill does not adopt the ACIP recommendation to introduce an exclusion that prevents the patenting of an activity that is "wholly offensive to the ordinary reasonable and fully informed member of the Australian public".15

Federal Court proceedings

In June 2010, Cancer Voices Australia and a breast cancer patient filed an application challenging the BRCA patents. This case is the first time an Australian court will examine the validity of gene patents. The final hearing is scheduled to be held in late February 2012. Ethical arguments will undoubtedly be raised by the applicants, though it remains to be seen whether the Federal Court will take a more expansive approach than that contemplated by the Bill.


If passed, the new legislation will have a significant impact on all stakeholders in the patent process -- including prospective patent applicants, generic competitors, researchers and the general community seeking to use a patented invention.

While the problems with gene patenting will be addressed to an extent by the Bill, it is likely to fall short of community expectations. In the meantime, all eyes will be on the results of the Federal Court case in relation to the BRCA genes.

Tip 1: File your request for examination as soon as practicable if you want the benefit of the current regime.

Schedule 1 of the Bill will not apply to current patent applications where a request for examination has been filed before the date of commencement of those changes (expected to be late 2012).

Tip 2: Take advantage of the new research and experimental use exemption and the regulatory approval ("springboard") exemption.

You should consider what steps can be taken now to take advantage of the new exemptions once they come into effect, which could occur by late 2011.

Tip 3: The research exemption will not extend to "research tools".

"Research tools", being something that is used to facilitate an experiment rather than being something that is the subject of the experiment, are not covered by the new research exemption.

Tip 4: There is a new requirement to disclose the usefulness of the patent in the specification and a new statutory definition of "useful".

You should consider and, if necessary, obtain advice on the impact of the new requirement to disclose the usefulness of the patent in the specification -- particularly given the new requirement to demonstrate a "specific, substantial and credible use".

Tip 5: Take extra care to ensure that no later amendments will be required.

If the Bill is passed, there will be a new prohibition on certain amendments being made after the date of filing. An attempt to add new material to the disclosure contained in the specification as filed could be refused outright or require you to lodge a new application.

1. ALRC, Genes and Ingenuity: Gene Patenting and Human Health, Report 99, August 2004.

2. ACIP, Patents and Experimental Use, October 2005; and ACIP, Patentable Subject Matter: Final Report, December 2010.

3. Senate Standing Committee on Community Affairs Inquiry into Gene Patents, 2009; Senate Community Affairs References Committee, Gene Patents, November 2010; Senate Legal and Constitutional Affairs Committee Inquiry into Patent Amendment (Human Genes and Biological Material) Bill 2010 (Cth).

4. Senate Standing Committee on Community Affairs Inquiry into Gene Patents, 2009; Senate Community Affairs References Committee, Gene Patents, November 2010; Senate Legal and Constitutional Affairs Committee Inquiry into Patent Amendment (Human Genes and Biological Material) Bill 2010 (Cth).

5. Explanatory Memorandum to the Bill.

6. Patent Act 1990 (Cth), s 18(2).

7. See Nicol D, "Recent decisions from the United States and Europe on patenting of biotechnology inventions and their potential impact on Australia" (2011) 24(2) IPLB.

8. Association for Molecular Pathology v United States Patent and Trademark Office No 9 Civ 4515 (SDNY).

9. Senate Standing Committee on Community Affairs, Gene Patents, 2010, ch 2.

10. GTG, "New position re BRCA testing", 2 December 2008, available at www.

11. Senate Standing Committee on Community Affairs Inquiry into Gene Patents, 2009; Senate Legal and Constitutional Affairs Committee Inquiry into Patent Amendment (Human Genes and Biological Material) Bill 2010 (Cth).

12. Patent Amendment (Human Genes and Biological Materials) Bill 2010 (No 2) (Cth).

13. Cancer Voices Australia (ABN 93 322 703 427) v Myriad Genetics Inc, Federal Court of Australia File NSD643/2010.

14. Above note 12.

15. Above note 2.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Catherine Logan
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.